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Multivariable Regression Analysis for OS and NRS† Post-
transplant variables at day 90 (±7) post-allo HCT §
OS NRS
Hospital stay (#5 vs. .5 days)* NS NS
Days of TPN (.0 vs. 0)* NS NS
PRBC transfusion (.0 vs. 0)* NS NS
Platelets transfusion (.0 vs. 0)* NS NS
Pneumonia episodes (.0 vs. 0)*,U NS p50.0008; 2.8
(1.5, 5.1)
Episodes of CMV reactivation
(.0 vs. 0)*
NS NS
Cumulative dose of steroids
(\2,650mg vs. $ 2,650mg)*
NS p50.001; 0.4
(0.2, 0.7)
Total days of steroids (\60 vs. $60)* NS NS
Dose of steroid at day 90 (67)
(\20 vs. $20mg/day)
NS NS
% weight loss (#10% vs. .10%)** NS NS
Acute GVHD (max grade) 0-I vs.
II vs. III-IV
NS NS
KPS at day 90 (67) (\80 vs. $80) p\0.0001; 4.7
(3.0, 7.4)
p\0.0001; 3.9
(2.0, 7.5)
Total bilirubin at day 90 (67)
(\1.1 vs. $1.1mg/dl)
NS NS
% Creatinine change ($30
vs.\30)*
p50.0002; 2.2
(1.5, 3.3)
NS
Albumin at day 90 (67)
\ 3.0 g/dl
vs. . 3.5 g/dl; 3.0-3.5 g/dl vs.
. 3.5 g/dl
p50.006; 2.5
(1.4, 4.5);
1.5 (0.9, 2.3)
p50.01; 3.2
(1.4, 7.1); 1.2
(0.6, 2.3)
Additional immunosuppressive
therapy (ies) (.0 vs. 0)^
NS NS
Additional anti-microbial(s)
(.0 vs. 0)^^
p50.002; 2.8
(1.5, 5.3)
NS
†Table entry: p-value (p) for the covariate effect;Hazard ratio (HR) (95%
CI).
§The effects of post-transplant variables were adjusted for baseline vari-
ables such as age, KPS and patient/donor CMV statuses in this regres-
sion, whenever appropriate/necessary. Statistical significance defined
as\0.05; NS: not significant (p$0.05). TPN: total parenteral nutrition.
*from hematopoietic engraftment until day 90 (67).
**from initiation of conditioning chemotherapy (baseline) until day 90
(67).
^additional anti-GVHD therapy(ies) apart from standard GVHD prophy-
laxis and glucocorticoids until day 90 (67).
^^additional antimicrobials apart from acyclovir, fluconazole or vorico-
nazole (whenever used for primary prohylaxis) and trimethoprin-
sulfamethoxazole (or equivalents).
Udevelopment of infiltrates requiring additional/alternative antimicro-
bials.
6 Oral Presentationscarcinoma infrequent after allo-HCT, we hypothesized that GI
could be observed in oral mucosal cells but not in nasal mucosal cells
of long-term HCT survivors.
Methods:We examined epithelial cells from buccal and nasal mu-
cosa of 71 subjects for GI at 15 microsatellite loci spanning 14 human
autosomes. The study population included long-term (4–22 yrs, n5
21) and short-term (2–3 months, n 5 15) survivors of myeloablative
allo-HCT, using GVHD prophylaxis with methotrexate (day 1, 3, 6
and 11) and cyclosporine (for 3–6 months). Controls included long-
term (4–12 yrs, n5 14) and short-term (2–3 months, n5 3) survivors
of myeloablative auto-HCT, 8 patients treated with intensive che-
motherapy without HCT and 5 healthy volunteers. DNA extracted
from peripheral blood leukocytes and cells of nasal and buccal mu-
cosa was PCR amplified for a panel of 15 microsatellite markers
(ABI-Identifiler). Fragment size analysis was done to identify novel
allele peaks (one that was absent in donor and recipient blood
pre-transplant but present in recipient mucosa post-transplant)
indicative of microsatellite instability (MSI).
Results: MSI was detected in 61% long-term allo-HCT survivors
in buccal mucosa, and in 5% long-term allo-HCT survivors in nasal
mucosa (p\0.001, Fisher exact test). MSI was detected in 12% short-
term allo-HCT survivors in buccal mucosa, and in 0% short-term
allo-HCT survivors in nasal mucosa (p 5 0.48). There was no asso-
ciation between MSI and history of clinical oral GVHD. None of the
auto-HCT survivors, patients treated with chemotherapy without
HCT or healthy volunteers showed MSI in buccal or nasal mucosal
cells. No MSI was observed in blood leukocytes of any of the above
patients or controls.
Conclusion: GI in long-term allo-HCT suvivors occurs fre-
quently in oral mucosal cells but rarely in nasal mucosal cells. As
GI was not observed in the oral mucosa of auto-HCT recipients
who received similar transplant conditioning, it cannot be due to cy-
totoxic therapy, but it should be due to a factor unique to allo-HCT,
ie, immunosuppressive drugs given for GVHD prophylaxis or graft vs
host oral mucosa reaction (even if clinically silent). The graft-vs-host
oral mucosa reaction may be more likely, as the GI was frequently
observed late posttransplant (after discontinuation of prophylactic
immunossupressive drugs) and rarely early posttransplant.
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HYPOALBUMINEMIA (\ 3.0 G/DL) AND POOR KARNOFSKY PERFOR-
MANCE (KPS\80) AT DAY 190 ARE INDEPENDENT PREDICTORS OF
WORSE NON-RELAPSE SURVIVAL (NRS) AND OVERALL SURVIVAL (OS)
IN ADULT ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
(ALLO-HCT) RECIPIENTS: RESULTS OF A MULTIVARIABLE ANALYSIS
Kharfan-Dabaja, M.A.1, Chavez, J.C.1, Fernandez-Vertiz, E.I.1,
Yu, D.2, Zhu, W.2, Perkins, J.1, Field, T.1, Ayala, E.1, Fernandez, H.1,
Alsina, M.1, Perez, L.1, Raychaudhuri, J.1, Ochoa-Bayona, J.L.1,
Brand, L.1, Sullivan, D.1, Anasetti, C.1 1Moffitt Cancer Center, Tampa,
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Acute GVHD (aGVHD) as a predictor of post allo-HCT survival
generally relies on criteria with significant inter-observer variability.
We study the impact of clinical, laboratory and pharmacologic pa-
rameters, during the immediate post-transplant phase [from hemato-
logic engraftment till day 90 (67)] on NRS and OS. In this analysis,
326 consecutive pts underwent allo-HCT between 09/2000 until 03/
2007; 26 pts who died within 90 days from the date of cell infusion and
3 syngeneic allo-HCT recipients were excluded from analysis. A total
of 297 (M/F 5 170/127) patients, median age 46 (range: 17–69) yrs
received an allo-HCT [MRD 5 154 (52%), MUD 5 109 (37%),
MMRD 5 3 (1%), MMUD 5 31 (10%)] using PBSC 5 261 (88%)
or BM 5 36 (12%) following myeloablative 5 99 (33%), RIC 5
174 (59%), or NMT5 24 (8%) for various hematologic malignancies
stratified by CIBMTR risk [low5 87 (30%); int5 85 (29%); high5
125 (42%)] usingvarious GVHD prophylaxis regimens [MTX-based5
244 (82%); MMF-based 5 53 (18%)]. Pre-transplant variables [sig-
nificant (p\0.05) or not-significant (NS) (p$0.05) in multivariable
Cox proportional hazards regression analysis] included: age ($55
vs.\ 55 yrs) [OS: p 5 0.035, HR 5 1.6 (95% CI: 1.0–2.4); NRS:
p 5 0.03, HR 5 2.0 (95% CI: 1.1–3.6)], donor-gender [OS: NS;
NRS: NS], cell source (BM vs. PB) [OS: NS; NRS: NS], baseline
KPS (#80 vs. .80) [OS: NS; NRS: NS], CIBMTR risk (low vs.
int. vs. high) [OS: NS; NRS: NS], regimen (myeloablative vs. RIC/
NMT) [OS: NS; NRS: NS], donor/recipient matching-status
(MRD, MUD, mismatched (ref)) [OS: p 5 0.03, MRD vs. ref:HR 5 2.7 (95% CI: 1.2–6.1), MUD vs. ref: HR 5 2.7 (95% CI:
1.2- 6.1); NRS: NS], CD341 dose (\ 3  106/kg, 3–7.9  106/kg,
$8 106/kg) [OS: NS; NRS: NS], GVHD prophylaxis (MTX-based
vs. MMF-based) [OS: NS; NRS: NS], recipient/donor CMV status
[OS: NS; NRS: NS]. Multivariable regression analysis of post-trans-
plant variables at day 90 show that a KPS\80 and hypoalbuminemia
\3.0 g/dl are independent predictors of worse NRS and OS. A wors-
ening serum creatinine ($30%) and additional antimicrobials apart
from standard prophylaxis are independent predictors of worse OS;
whereas pneumonia (.0 episode by day 90) and cumulative dose of
prednisone exceeding 2,650 mg are independent predictors of worse
NRS. A KPS \80 and hypoalbuminemia (\3.0 g/dl), at day 90,
important predictors of survival that should be considered when
prognosticating outcome after allo-HCT.12
RAPID IMMUNOSUPPRESSION TAPER FOLLOWING REDUCED INTENSITY
HCT FROM RELATED DONOR IS TOLERABLE BUT DOES NOT IMPROVE
OUTCOMES OF ADVANCED HEMATOLOGIC MALIGNANCIES
Krijanovski, O.1, Krijanovski, Y.2, Khaled, Y.1, Cummings, T.1,
Braun, T.1, Reddy, P.1, Peres, E.1, Mineishi, S.1, Kitko, C.1, Choi, S.1,
Oral Presentations 7Yanik, G.1, Pawarode, A.1, Paczesny, S.1, Levine, J.E.1 1University of
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We have previously showed that, despite the significant reduc-
tion of transplant-related mortality (TRM) achieved by using
reduced intensity conditioning (RIC), relapse continues to be a ma-
jor cause of failure, especially in advanced-stage hematologic ma-
lignancies. In order to improve relapse-free survival in the setting
of reduced intensity sibling donor transplants for advanced hema-
tologic malignancies, our group has tested a modified Fludara-
bine/Busulfan RIC regimen (fludarabine 150 mg/m2 IV, busulfan
6 mg/kg IV, total lymphoid irradiation 2 Gy) with a rapid post-
transplant immunosuppression (IS) taper (start day 28, finish day
63) in a prospective single arm phase II study. The rapid taper
was intended to facilitate a GVL effect that hopefully would trans-
late into improved DFS. Patients without progression who did not
develop GVHD by d100 received planned donor lymphocyte infu-
sion (DLI) 5  107 CD31/kg. 45 pts (median f/u 918d; range 100–
1835d) have been treated between 8/2003- 2/2008. The median age
was 56y (2–67y); 19 (42%) failed previous autologous HCT. Five
patients received DLI. Forty patients received HSC from 6/6
HLA matched and 5 from 5/6 HLA matched related donors. Rapid
tacrolimus taper reliably induced GVHD grade 2–4 in the study
population (73 6 6%) by day 100 at a median of 46d (range, 18–
98d). Extensive chronic GVHD developed in 6567% of patients.
GVHD in this context was rarely fatal (7 GVHD-related deaths) re-
sulting in 2-year NRM of 24 6 7%. Outcomes were analyzed for
the whole group and by stratification according to risk of relapse af-
ter non-myeloablative HSCT.Stratification of the Study Patients According to the Esti-
mated Risk of Relapse After NMA HSCT (1)
High/Standard-risk disease n528 Low-risk disease n517
AML (de novo) 4 Follicular lymphoma, low grade 4
AML (secondary) 3 MAntle cell lymphoma 4
AML (treatment-related) 2 DLBCL/t-DLBCL, CR 3
MDS 6 NHL/AITL, CR 1
CML-BC 1 MM, CR 5
Ph1ALL, CR2 1
Hodgkin’s disease, refractory 4
MM, refractory 5
t-DLBCL, refractory 1
CLL, refractory 1
(1)-kahl, c., et al. Bood 2007; 110:7 2744-48The 2-year OS and PFS for all pts was 38617% and 3567% re-
spectively, with superior PFS seen in low risk vs high/standard
risk pts (526 13% vs 2668% p 5 0.03). A higher cumulative in-
cidence of progression in high/standard risk pts (6369% vs 0%,
p5 0.0001) accounted for most of the difference in survival. How-
ever, when compared to similar risk group pts in our prior trial
(Levine, et al, BBMT 2003) that utilized identical conditioning,
but a conventional IS taper, there were no differences in PFS for
low risk (58% vs 50%, p 5 NS) or high risk pts (29% vs 23%,
p 5 NS). TRM rates were similar in both trials (32% vs 24%,
p 5NS). Thus, while a rapid IS taper in this RIC setting induces
GVHD that is usually non-lethal, the desired GVL effect did not
manifest itself in terms of improvements in PFS for low or high
risk pts.
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THE ECONOMIC COSTS TO US HOSPITALS OF INVASIVE FUNGAL INFEC-
TIONS IN HEMATOPOIETIC STEM CELL AND BONE MARROW TRANS-
PLANT PATIENTS
Menzin, J.1, Jackel, J.L.1, Friedman, M.1, Korn, J.R.1, Perfect, J.2,
Langston, A.3, Prasad, M.4, Papadopoulos, G.4 1Boston Health Economics,
Inc., Waltham, MA; 2Duke Medical Center, Durham, NC; 3Emory
Winship Cancer Institute, Atlanta, GA; 4Schering-Plough Corporation,
Kenilworth, NJ
Background: Patients undergoing hematopoietic stem cell or
bone marrow transplants (HSC/BMTs) are at an increased risk of
contracting invasive fungal infections (IFIs). Data on the economic
burden of these infections are sparse.Methods: This retrospective matched cohort study used data
from the 2004 and 2005 Healthcare Cost and Utilization Pro-
ject Nationwide Inpatient Sample (HCUP-NIS) to assess the
excess mortality, lengths of stay, and costs of IFIs in HSC/
BMT recipients. Patients were selected for the IFI cohort if
they had ICD-9-CM codes indicating an HSC/BMT procedure
and an IFI during their hospital stay. Patients were matched to
controls (transplant recipients who had no diagnosis of IFI)
based on age (within 10 years), sex, hospital region, hospital
type, year in hospital (2004 or 2005), and type of transplant (al-
logeneic HSC/BMT, or autologous HSC/BMT). Analyses of
mortality, lengths of stay, and costs were reported overall and
by type of transplant.
Results: In 2004 and 2005, 4,661 patients received an HSC or
BMT. Of these, 111 (2.4%) had a diagnosis of an IFI in hospi-
tal. Almost all IFI patients (98%) could be matched to controls.
After matching, the mean (6SD) age was 37.8 (621.6) years,
62% of patients were male, and patients were predominately
white. Common comorbidities among patients with an HSC/
BMT and an IFI included fluid and electrolyte disorders
(46.8%), hypertension (16.5%), and coagulopathy (13.8%). As-
pergillosis was the most common type of mycosis followed by
candidiasis. Overall, IFIs in HSC/BMT recipients were associ-
ated with a 6-fold increase in mortality (23.2% among patients
with IFIs vs 3.8% among patients without IFIs), excess mean
(6SD) lengths of stay of 16.2 (65.0) days, and excess mean
(6SD) costs of $51,655 (6$12,399) per patient. Patients with
allogeneic HSC/BMT had higher excess mortality and excess
lengths of stay but lower excess costs than patients with autol-
ogous HSC/BMT.
Conclusions: The excess burden of IFIs among HSC/BMT re-
cipients is high. Improved efforts to prevent these infections may
yield both clinical and economic benefits.14
STANDARD AND REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANTATIONS (HSCT) FROM RELATED AND UNRE-
LATED DONORS FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
A LONG-TERM FOLLOW-UP (10 YEARS) STUDY FROM THE EBMT
REGISTRY
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Koza, V.4, Ruutu, T.5, Russel, N.6, Verdonck, L.7, Milligan, D.8,
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Nottingham, United Kingdom; 7University Medical Centre Utrecht,
Utrecht, Netherlands; 8 Birmingham Heartlands Hospital, Birming-
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10University Hospital Kralovske Vinohrady, Prague, Czech Republic;
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This retrospective analysis concerned 374 patients (pts) who un-
derwent an allo-HSCT for CLL reported to the EBMT registry.
There were 282 M and 92 F, median age 53 years (24–69). The in-
terval diag-transp. was 53 months (3–308). Forty five pts (12%)
have received a previous HSCT. At transplant, 302 among 323
evaluated pts had a good performance status (PS) (93%), 51 pts
were in CR (14%), 163 in PR (45.5%), 39 in SD (11.5%) and
105 in PD (29%) among 353 evaluated pts. As conditioning, 292
pts received a standard (std) one and 82 RIC; 314 pts received
PBSC, 55 BM and 5 cord blood cells from 202 HLA siblings
(Sib), 2 mismatched related donors and 170 unrelated donors
(UD). There were 136 (36%) sex-mismatched, 150 pairs (40%)
had an ABO incomp. (61 min., 99 maj.). There were 359 pts en-
grafted, 201 AGVHD (gr I: 76, gr II : 79 , gr III: 30 and gr
IV:16) and 15 cGVHD (75 lim., 78 ext.). At day 100, the cumula-
tive incidence (CI) of AGVHD for the total population was 17%
(13–22) for gr I, 31% (26–36) for gr $ II. [Sib: 19% (13–25) gr
I and 27% (21–34) gr $ II; UD: 16% (9–22) gr I and 38%
(29–47) gr $ II].
